Royal Bank of Canada’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-34,774
| Closed | -$656K | – | 7388 |
|
|
2019
Q3 | $656K | Sell |
34,774
-28,921
| -45% | -$331K | ﹤0.01% | 3662 |
|
|
2019
Q2 | $749K | Sell |
63,695
-2,810
| -4% | -$34K | ﹤0.01% | 3556 |
|
|
2019
Q1 | $908K | Buy |
66,505
+1,773
| +3% | +$23K | ﹤0.01% | 3266 |
|
|
2018
Q4 | $663K | Buy |
64,732
+18,950
| +41% | +$243K | ﹤0.01% | 3492 |
|
|
2018
Q3 | $762K | Buy |
45,782
+7,847
| +21% | +$142K | ﹤0.01% | 3589 |
|
|
2018
Q2 | $598K | Sell |
37,935
-18,875
| -33% | -$287K | ﹤0.01% | 3658 |
|
|
2018
Q1 | $721K | Buy |
56,810
+23,121
| +69% | +$334K | ﹤0.01% | 3417 |
|
|
2017
Q4 | $386K | Buy |
33,689
+24,614
| +271% | +$275K | ﹤0.01% | 3964 |
|
|
2017
Q3 | $111K | Buy |
9,075
+6,649
| +274% | +$69.3K | ﹤0.01% | 4944 |
|
|
2017
Q2 | $28K | Sell |
2,426
-187,827
| -99% | -$3.47M | ﹤0.01% | 5415 |
|
|
2017
Q1 | $3.96M | Sell |
190,253
-16,644
| -8% | -$368K | ﹤0.01% | 2075 |
|
|
2016
Q4 | $4.3M | Buy |
206,897
+10,563
| +5% | +$275K | ﹤0.01% | 2055 |
|
|
2016
Q3 | $6.43M | Buy |
196,334
+25,980
| +15% | +$791K | ﹤0.01% | 1746 |
|
|
2016
Q2 | $4.25M | Buy |
+170,354
| New | +$4.61M | ﹤0.01% | 2006 |
|
|
2016
Q1 | – | Sell |
-107
| Closed | -$3K | – | 6830 |
|
|
2015
Q4 | $3K | Sell |
107
-1,356
| -93% | -$45.9K | ﹤0.01% | 6310 |
|
|
2015
Q3 | $48K | Sell |
1,463
-2,316
| -61% | -$98.5K | ﹤0.01% | 5154 |
|
|
2015
Q2 | $200K | Sell |
3,779
-4,353
| -54% | -$158K | ﹤0.01% | 4366 |
|
|
2015
Q1 | $234K | Sell |
8,132
-6,913
| -46% | -$190K | ﹤0.01% | 4122 |
|
|
2014
Q4 | $438K | Sell |
15,045
-5,277
| -26% | -$94.7K | ﹤0.01% | 3704 |
|
|
2014
Q3 | $258K | Buy |
20,322
+1,794
| +10% | +$27.1K | ﹤0.01% | 4010 |
|
|
2014
Q2 | $372K | Buy |
+18,528
| New | +$261K | ﹤0.01% | 3688 |
|
Royal Bank of Canada's ALDR Position: Q4 2019 in Review
Royal Bank of Canada sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 34,774 shares — an estimated $656K sold.
Royal Bank of Canada first reported a position in ALDR in Q2 2014 and held it in 21 quarters. The position peaked at $6.43M in Q3 2016. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Royal Bank of Canada reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Royal Bank of Canada sold 34,774 Alder Biopharmaceuticals shares in Q4 2019, an estimated $656K.
- Royal Bank of Canada first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 21 quarters.
- Royal Bank of Canada's Alder Biopharmaceuticals position peaked at $6.43M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Royal Bank of Canada's 13F filing for Q4 2019, filed 14 Feb 2020.